Eli Lillys Phenotypic Drug Discovery (PD2) Program |
 |
|
|
|
What is the PD2 Program?
 |
An innovative way for researchers to see if their compounds are of interest to Lilly’s drug development efforts, which offers:
- Confidential compound submission via web-based interface
- No-cost access to phenotypic assay panel for investigators
- Full data report provided to investigator
- Basis for a collaboration agreement if findings are promising
|
|
|
|
|
|
| What is Eli Lilly looking for? |
|
|
Small chemical molecules, natural products and natural product derivatives, excluding proteins, peptides, antisense oligonucleotides and RNAi’s. PD2 assay modules screen for compounds that:
|
- Selectively enhance apoE secretion through non-LXRβ mechanisms (for Alzheimers Disease)
|
- Block the cell cycle in G2 or M phase, are selectively anti-proliferative to rapidly growing cells, and act through non-tubulin mechanisms; or inhibit angiogenesis but do not show inhibition of known angiogenic receptor tyrosine kinases (for cancer)
|
- Act as glucose-dependent, insulin specific secretagogues (for Diabetes)
|
- Increase osteoblast formation in rodent and human cellular assays through a non-glycogen synthase kinase (GSK) mechanism (for bone formation)
|
| USC needs to have rights to transfer the material, and the ability to grant an exclusive option. You also need to have at least a 3-5mg sample of the compound that is at least 90% pure available to send to Eli Lilly if requested. |
|
|
|
|
|
|
|
| What's the process? |
|
|
1. Request an affiliation code from the USC Stevens Institute
(Contact Stephanie Valencia at horngs@usc.edu)
|
2. Create a personal account on the PD2 web site
(https://pd2.lilly.com/pd2Web/ Click on “Create a New Account”)
|
3. Upload and submit structures in standard format files (MOL, SDF or SMI*), or
enter using the drawing tool (Marvin Sketch) on the website
|
|
4. Cheminformatics analyses screen for compounds with attractive profiles.
- An overall desirability score is computed and returned to the PD2 site.
- All information associated with the submission is removed from the database
and is not shared with Eli Lilly.
|
5. If compounds pass the selection criteria, Lilly provides barcoded vials and shipping
instructions to the investigator for submission of a 3-5mg sample that should be at
least 90% pure based on contemporary analytical characterization.
|
|
6. Lilly prepares and tests activity in phenotypic assay modules and secondary screens. Any
leftover materials are destroyed. The investigator receives a report with a biological profile
of the compounds tested.
|
7. At this point, Lilly may invite the investigator/institution to disclose the structure of the
selected compound under confidentiality, potentially leading to a collaboration or licensing
agreement. Alternatively, the investigator/institution may decide not to disclose the
structure.
|
| We encourage you to review the website at https://pd2.lilly.com/ for additional details of the program, including details of the cheminformatics analyses, assay modules, report contents and related information. |
|
|
|
|
|
|
|
Click here to download a printable version of this information. |
|
|
ABOUT US
